OTCM
BZYR
Market cap6mUSD
Jul 28, Last price
0.05USD
1D
0.00%
1Q
-11.11%
Jan 2017
-36.00%
IPO
-26.15%
Name
Burzynski Research Institute Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-1m
L+45.74%
CFO
-524k
L+109.92%
Profile
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2019‑02 | 2018‑02 | 2017‑02 | 2016‑02 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1,335 | 916 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,335) | (916) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (1,335) | (916) | |||||||
Net income | (1,335) 45.74% | (916) -6.18% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 524 | 247 | |||||||
BB yield | -17.34% | -5.11% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (1) | (934) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (524) | (250) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 524 | 247 | |||||||
FCF | (1,324) | (903) | |||||||
| Balance | |||||||||
Cash | 1 | 934 | |||||||
Long term investments | |||||||||
Excess cash | 1 | 934 | |||||||
Stockholders' equity | (127,959) | (126,623) | |||||||
Invested Capital | 127,934 | 126,610 | |||||||
ROIC | |||||||||
ROCE | 5,315.57% | 6,675.11% | |||||||
| EV | |||||||||
Common stock shares outstanding | 131,448 | 131,448 | |||||||
Price | 0.02 -37.44% | 0.04 | |||||||
Market cap | 3,022 -37.44% | 4,831 | |||||||
EV | 3,021 | 4,830 | |||||||
EBITDA | (1,335) | (916) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||